WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561616
CAS#: 89667-40-3
Description: Isbogrel is a selective thromboxane A2 (TXA2) synthase inhibitor.
Hodoodo Cat#: H561616
Name: Isbogrel
CAS#: 89667-40-3
Chemical Formula: C18H19NO2
Exact Mass: 281.14
Molecular Weight: 281.350
Elemental Analysis: C, 76.84; H, 6.81; N, 4.98; O, 11.37
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Isbogrel; CV-4151; CV 4151; CV4151;
IUPAC/Chemical Name: (E)-7-Phenyl-7-pyridin-3-ylhept-6-enoic acid
InChi Key: UWPBQLKEHGGKKD-GZTJUZNOSA-N
InChi Code: InChI=1S/C18H19NO2/c20-18(21)12-6-2-5-11-17(15-8-3-1-4-9-15)16-10-7-13-19-14-16/h1,3-4,7-11,13-14H,2,5-6,12H2,(H,20,21)/b17-11+
SMILES Code: O=C(O)CCCC/C=C(C1=CC=CC=C1)/C2=CC=CN=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 281.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Miyatake T, Kubota S, Miyazaki K, Watanabe S, Mafune N, Murashita T, Yasuda K. Analysis of cardiac function during hyperacute rejection: effects of PAF antagonist, TXA(2) inhibitor/antagonists, and nitroglycerin. Transplant Proc. 2000 Aug;32(5):999-1000. PubMed PMID: 10936319.
2: Umetani K, Tamura K, Komori S, Watanabe A, Ishihara T, Mochizuki S, Li B, Ijiri H. Inhibitory effect of CV4151, a thromboxane A2 synthetase inhibitor, on ventricular arrhythmias induced by coronary artery occlusion in rats. Jpn Circ J. 1996 Jun;60(6):349-54. PubMed PMID: 8844301.
3: Terashita Z, Imura Y, Nishikawa K. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings. J Lipid Mediat Cell Signal. 1996 Jan;13(1):1-8. PubMed PMID: 8821806.
4: Hsu LY, Lee CF, Chou TC, Ding YA. 2-Heteroaryl 2-substituted phenylketone derivatives and their inhibitory activity on platelet aggregation. J Pharm Pharmacol. 1995 Sep;47(9):762-7. PubMed PMID: 8583390.
5: Imura Y, Kiyota Y, Nagai Y, Nishikawa K, Terashita Z. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995 Jul 1;79(1):95-107. Erratum in: Thromb Res 1996 Jul 1;83(1):111-2. Thromb Res 1996 Oct 15;84(2):143. PubMed PMID: 7495108.
6: Ackerley N, Brewster AG, Brown GR, Clarke DS, Foubister AJ, Griffin SJ, Hudson JA, Smithers MJ, Whittamore PR. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. J Med Chem. 1995 May 12;38(10):1608-28. PubMed PMID: 7752186.
7: Terashita Z, Imura Y, Kawamura M, Kato K, Nishikawa K. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Thromb Res. 1995 Mar 1;77(5):411-21. Erratum in: Thromb Res 1996 Oct 15;84(2):144. Thromb Res 1996 Jul 1;83(1):113-5. PubMed PMID: 7778056.
8: Yamaguchi M, Maruyama N, Koga T, Kamei K, Akima M, Kuroki T, Hamana M, Ohi N. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. VI. Indazole derivatives. Chem Pharm Bull (Tokyo). 1995 Feb;43(2):332-4. PubMed PMID: 7728936.
9: Matsumoto T, Ashida Y, Tsukuda R. Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig. J Pharmacol Exp Ther. 1994 Jun;269(3):1236-44. PubMed PMID: 8014867.
10: Sasaki Y, Ishiguro N, Miura T. Effects of thromboxane A2 synthetase inhibitor (CV-4151) on reperfused skeletal muscle in rats. Eur Surg Res. 1994;26(2):101-7. PubMed PMID: 8005166.
11: Kito G, Tanabe M, Terashita Z. [Effect of CV-4151 on the cerebral hypoperfusion and production of thromboxane A2 following complete cerebral ischemia-reperfusion in dogs]. Nihon Yakurigaku Zasshi. 1993 Dec;102(6):413-20. Japanese. PubMed PMID: 8282273.
12: Häyry P, Mennander A, Paavonen T, Räisänen A, Ustinov J. Role of thromboxane in the generation of allograft arteriosclerosis in chronic rejection. Transplant Proc. 1993 Feb;25(1 Pt 1):603-4. PubMed PMID: 8438433.
13: Kawakage M, Shirakura S, Karasawa A, Takeda M, Miki I, Ishii A, Kubo K. Beneficial effect of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate on collagen-induced coronary ischemia in guinea-pigs. Arzneimittelforschung. 1991 Dec;41(12):1246-50. PubMed PMID: 1815524.
14: Yasuda K, Matsui Y, Goda T, Sakuma M, Go K. [Chronic arterial occlusive diseases--drug therapy and thromboxane A2 synthetase inhibitor]. Nihon Rinsho. 1991 Sep;49(9):2149-54. Japanese. PubMed PMID: 1960880.
15: Asai F, Ito T, Ushiyama S, Matsuda K, Oshima T. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate. Arzneimittelforschung. 1991 May;41(5):506-10. PubMed PMID: 1898421.
16: Hattori R, Kodama K, Takatsu F, Yui Y, Kawai C. Randomized trial of a selective inhibitor of thromboxane A2 synthetase, (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), for prevention of restenosis after coronary angioplasty. Jpn Circ J. 1991 Apr;55(4):324-9. PubMed PMID: 2046138.
17: Watts IS, Wharton KA, White BP, Lumley P. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Br J Pharmacol. 1991 Feb;102(2):497-505. PubMed PMID: 1826620; PubMed Central PMCID: PMC1918008.
18: Kuroe K, Kurokawa T, Nishikimi M, Nonami T, Harada A, Nakao A, Takagi H. Effects of thromboxane A2 synthetase inhibitor on postischemic liver injury in rats. Eur Surg Res. 1991;23(1):20-6. PubMed PMID: 1879452.
19: Imura Y, Terashita Z, Nishikawa K. The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage. Thromb Res. 1990 Jul 1;59(1):195-205. PubMed PMID: 2119075.
20: Watts IS, White BP, Wharton KA, Lumley P. Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo. Br J Pharmacol. 1989 Dec;98 Suppl:842P. PubMed PMID: 2611538.
